Alanko A, Heinonen E, Scheinin T, Tolppanen E M, Vihko R
Cancer. 1985 Oct 1;56(7):1696-700. doi: 10.1002/1097-0142(19851001)56:7<1696::aid-cncr2820560738>3.0.co;2-n.
Estrogen and progesterone receptors (ER/PR) were measured in primary tumors and metastases of 397 breast cancer patients. Survival following mastectomy was significantly longer in patients with ER and PR positive tumors, as was survival after first recurrence. The prognostic value of ER and PR was compared with such clinical factors as disease-free interval (DFI) and the dominant site of first metastasis by Cox's regression analysis. With all the different therapy modalities long DFI was the best prognostic indicator. However, in the patient group treated with endocrine therapy, ER and PR positivity was the best prognostic indicator, suggesting that longer survival in receptor positive patients was related to the response to endocrine treatment.
对397例乳腺癌患者的原发性肿瘤和转移灶进行了雌激素和孕激素受体（ER/PR）检测。ER和PR阳性肿瘤患者乳房切除术后的生存期明显更长，首次复发后的生存期也是如此。通过Cox回归分析，将ER和PR的预后价值与无病间期（DFI）和首次转移的主要部位等临床因素进行了比较。在所有不同的治疗方式中，长DFI是最佳的预后指标。然而，在内分泌治疗的患者组中，ER和PR阳性是最佳的预后指标，这表明受体阳性患者生存期更长与内分泌治疗反应有关。
